Background: Patients undergoing complex percutaneous coronary intervention (PCI) carry a higher incidence of in-stent restenosis. This could be due to late acquired malposition, ne-ointimal hyperplasia, increased coagulation activity, in patients having a higher incidence of coronary atherosclerosis, rupture plaque and acute coronary syndrome. Rivaroxiban, selectively targets activated factor X (X...
Background: Patients undergoing complex percutaneous coronary intervention (PCI) carry a higher incidence of in-stent restenosis. This could be due to late acquired malposition, ne-ointimal hyperplasia, increased coagulation activity, in patients having a higher incidence of coronary atherosclerosis, rupture plaque and acute coronary syndrome. Rivaroxiban, selectively targets activated factor X (X...